|
|
Prospective Oral HPV and Risk of Head and Neck Cancers
|
5R21CA152785-02
|
$181,341
|
$181,341
|
BURK, ROBERT
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Targeted therapy of pancreatic cancer with in vivo radionuclide generator
|
5R21CA156088-02
|
$216,630
|
$216,630
|
DADACHOVA, EKATERINA
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
DNA mismatch repair and cancer in murine models
|
5R01CA076329-15
|
$376,370
|
$376,370
|
EDELMANN, WINFRIED
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Proton-coupled folate/antifolate transport
|
5R01CA082621-14
|
$513,291
|
$513,291
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis
|
1R01CA170911-01
|
$346,525
|
$173,263
|
Libutti, Steven
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
The transcriptional basis of tumor promotion
|
5R01CA104292-09
|
$354,879
|
$354,879
|
LOCKER, JOSEPH
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Development of Novel Drugs to Alleviate CPT-11 Toxicity
|
1R01CA161879-01A1
|
$315,319
|
$315,319
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Par1-substrates responsible for CagA-mediated pathogenesis of Helicobacter pylori
|
1R01CA160790-01A1
|
$511,917
|
$511,917
|
MUESCH, ANNE
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis
|
1R01CA163907-01A1
|
$364,002
|
$364,002
|
SCHWARTZ, EDWARD
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
5U10CA014958-38
|
$101,749
|
$5,087
|
Sparano, Joseph
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Proteome Bead-Display for Discovery of Tumor Antigens
|
2R44CA137948-02A1
|
$487,788
|
$487,788
|
Lim, Mark
|
AMBERGEN, INC
|
|
|
Global Proteomic Screening by MALDI Spectrometric Imaging of Protein-Bead Arrays
|
5R43CA161965-02
|
$149,865
|
$74,933
|
Lim, Mark
|
AMBERGEN, INC
|
|
|
Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection
|
5R44CA119565-07
|
$999,610
|
$999,610
|
Sears, Christopher
|
AMBERGEN, INC
|
|
|
AmberGen"Phase I, Topic 309, Label-Free Multivariate Cancer Diagnosis"
|
N43CO120071-000
|
$199,767
|
$199,767
|
SEARS, CHRISTOPHER
|
AMBERGEN, INC
|
|
|
Community Clinical Oncology Program
|
5U10CA037422-25
|
$4,499,349
|
$764,889
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
3U10CA021661-36S1
|
$172,284
|
$22,397
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-36
|
$12,915,055
|
$1,678,957
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
RTOG Biospecimen Repository
|
5U24CA114734-07
|
$500,745
|
$150,224
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Multi-functional Esophaeal Theranostic Delivery System
|
N43CO110053-001
|
$180,000
|
$180,000
|
SHENOY, NARMADA
|
ARAVASC, INC.
|
|
|
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors
|
1R41CA174031-01
|
$266,641
|
$266,641
|
Jones, Barry
|
ARISAPH PHARMACEUTICALS, INC.
|
|
|
Mutation-Specific p53 Antibodies as Biomarkers of Pancreatic Cancer
|
1R21CA164593-01
|
$212,556
|
$212,556
|
ANDERSON, KAREN
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
A Center for the Convergence of Physical Science and Cancer Biology
|
5U54CA143862-04
|
$1,680,677
|
$1,680,677
|
Davies, Paul
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Navigation from Community to Clinic to promote CRC Screening in Underserved Popul
|
1R01CA162393-01A1
|
$639,914
|
$639,914
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Geospatial Factors and Impacts II
|
2R01CA126858-05
|
$403,837
|
$201,919
|
MOBLEY, LEE
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Prevention of EtOH-induced promotion of hepatocarcinogenesis by genistein/soy
|
1R21CA169389-01
|
$193,140
|
$193,140
|
Ronis, Martin
|
ARKANSAS CHILDREN'S HOSPITAL RES INST
|
|
|
Identification of microRNA Biomarkers for Colon Cancer Recurrence Risk Stratifica
|
5R44CA138038-04
|
$301,582
|
$301,582
|
Mambo, Elizabeth
|
ASURAGEN, INC.
|
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-23
|
$486,165
|
$72,925
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
|
Guideline-based surveillance and treatment of hepatocellular carcinoma
|
5R01CA160738-02
|
$324,738
|
$324,738
|
Davila, Jessica
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Advanced glycation end products and colorectal cancer risk in women
|
5R03CA156626-02
|
$80,193
|
$80,193
|
JIAO, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
BRIT1, A NOVEL HEPATOCELLULAR CARCINOMA TUMOR SUPPRESSOR
|
5R21CA161513-02
|
$171,064
|
$171,064
|
LI, KAIYI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Steroid Receptor Coactivator-2 as a key hepatic tumor suppressor and circadian me
|
1F31CA171350-01
|
$26,232
|
$26,232
|
STASHI, ERIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Regulation of cell growth by RNA binding proteins
|
5R01CA100070-10
|
$258,839
|
$258,839
|
TIMCHENKO, NIKOLAI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Role of Age in Liver Cancer
|
5R01CA159942-02
|
$324,738
|
$324,738
|
TIMCHENKO, NIKOLAI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Familial and Early Onset Colorectal Cancer
|
5R01CA072851-17
|
$332,512
|
$332,512
|
BOLAND, CLEMENT
|
BAYLOR RESEARCH INSTITUTE
|
|
|
JC Virus and Human Colorectal Neoplasia
|
5R01CA098572-08
|
$267,374
|
$267,374
|
BOLAND, CLEMENT
|
BAYLOR RESEARCH INSTITUTE
|
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-28
|
$607,994
|
$66,879
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Design of a real-time dosimetry prototype for use with external beam radiotherapy
|
1R41CA174042-01
|
$149,800
|
$74,900
|
Izaguirre, Enrique
|
BEST MEDICAL INTERNATIONAL, INC.
|
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-14
|
$95,411
|
$4,771
|
BUBLEY, GLENN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Role of Fibroblasts, Myeloid Cells and Matrix in PDAC
|
5U01CA151925-03
|
$647,718
|
$647,718
|
KALLURI, RAGHU
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Inhibition of angiogenesis by thrombospondin-1 (A2)
|
5R01CA130895-04
|
$347,364
|
$347,364
|
LAWLER, John
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Optimizing localized therapy for primary liver cancer: a clinical trial and model
|
5K23CA139005-04
|
$169,560
|
$169,560
|
Miksad, Rebecca
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Role of POZ-zinc finger proteins in tumorigenesis.
|
5R01CA102142-08
|
$330,937
|
$109,209
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
EndoPulse System for Endoscopic Ultrasound-Guided Therapy of Pancreatic Carcinoma
|
2R44CA150484-02
|
$1,019,109
|
$1,019,109
|
NUCCITELLI, RICHARD
|
BIOELECTROMED CORPORATION
|
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S1
|
$300,000
|
$39,000
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S2
|
$139,989
|
$18,199
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
|
The MB-CCOP at Boston Medical Center
|
5U10CA139519-03
|
$310,336
|
$40,344
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
|
A Risk Prediction Model for Colorectal Cancer Screening
|
5R01CA131197-05
|
$430,622
|
$430,622
|
SCHROY, PAUL
|
BOSTON MEDICAL CENTER
|
|
|
Bilateral oophorectomy and cancer risk and mortality in African American women
|
5R03CA162103-02
|
$61,751
|
$20,378
|
Boggs, Deborah
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
1UM1CA164974-01A1
|
$2,196,670
|
$439,334
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
A Follow-up Study for Causes of Illness in Black Women
|
5R01CA058420-19
|
$1,716,455
|
$858,228
|
Rosenberg, Lynn
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Total relevant funding to Digestive Diseases for this search: $459,809,564
|
